FOLH1 and prostate neoplasm: In 2022, Cheng et al. reported that the inclusion of the highly specific PSMA-targeting ligand enabled 111In/177Lu-nanotexaphyrin to preferential accumulation in PSMA-positive prostate tumors and successfully inhibited tumor growth in a xenograft model [102].